- Home
- IMNM vs ARCT Comparison
IMNM vs ARCT Comparison
Compare IMNM & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- ARCT
- Stock Information
- Founded
- IMNM 2006
- ARCT 2013
- Country
- IMNM United States
- ARCT United States
- Employees
- IMNM N/A
- ARCT N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- IMNM Health Care
- ARCT Health Care
- Exchange
- IMNM Nasdaq
- ARCT Nasdaq
- Market Cap
- IMNM 747.7M
- ARCT 602.7M
- IPO Year
- IMNM 2020
- ARCT N/A
- Fundamental
- Price
- IMNM $12.09
- ARCT $20.60
- Analyst Decision
- IMNM Strong Buy
- ARCT Strong Buy
- Analyst Count
- IMNM 4
- ARCT 7
- Target Price
- IMNM $28.75
- ARCT $65.00
- AVG Volume (30 Days)
- IMNM 761.5K
- ARCT 338.5K
- Earning Date
- IMNM 11-07-2024
- ARCT 11-12-2024
- Dividend Yield
- IMNM N/A
- ARCT N/A
- EPS Growth
- IMNM N/A
- ARCT N/A
- EPS
- IMNM N/A
- ARCT N/A
- Revenue
- IMNM $10,784,000.00
- ARCT $163,866,000.00
- Revenue This Year
- IMNM N/A
- ARCT $13.46
- Revenue Next Year
- IMNM N/A
- ARCT $5.17
- P/E Ratio
- IMNM N/A
- ARCT N/A
- Revenue Growth
- IMNM 62.73
- ARCT N/A
- 52 Week Low
- IMNM $6.93
- ARCT $17.52
- 52 Week High
- IMNM $30.96
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- IMNM 36.69
- ARCT 42.91
- Support Level
- IMNM $11.81
- ARCT $20.00
- Resistance Level
- IMNM $12.44
- ARCT $21.86
- Average True Range (ATR)
- IMNM 0.68
- ARCT 1.49
- MACD
- IMNM -0.11
- ARCT -0.35
- Stochastic Oscillator
- IMNM 11.61
- ARCT 18.04
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.